Angeliq patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8906890 BAYER HLTHCARE Very low-dosed solid oral dosage forms for HRT
Oct, 2031

(8 years from now)

Angeliq is owned by Bayer Hlthcare.

Angeliq contains Drospirenone; Estradiol.

Angeliq has a total of 1 drug patent out of which 0 drug patents have expired.

Angeliq was authorised for market use on 28 September, 2005.

Angeliq is available in tablet;oral dosage forms.

The generics of Angeliq are possible to be released after 22 October, 2031.

Drugs and Companies using DROSPIRENONE; ESTRADIOL ingredient

Market Authorisation Date: 28 September, 2005

Treatment: NA


How can I launch a generic of ANGELIQ before it's drug patent expiration?
More Information on Dosage

ANGELIQ family patents

Family Patents

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic